Markus Reichlin

Markus Reichlin

Auto-generated profile, based on publicly available information

Markus Reichlin

Institute of Integrative Biology, Department of Environmental Systems Science, ETH Zürich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2023 in Gut Microbes
Verified
Journal Article
Open access
FKFabienne Kurt
Fabienne Kurt
GLGabriel Leventhal
Gabriel Leventhal
MSMarianne Spalinger
Marianne Spalinger
LALaura Anthamatten
Laura Anthamatten
PBPhilipp Rogalla von Bieberstein
Philipp Rogalla von Bieberstein
TWTomas de Wouters
Tomas de Wouters
The success of fecal microbiota transplants (FMT) has provided the necessary proof-of-concept for microbiome therapeutics. Yet, feces-based therapies have many associated risks and uncertainties, and hence defined microbial consortia that modify the microbiome in a targeted manner have emerged as a promising safer alternative to FMT. The development of such live biotherapeutic products has important challenges, including the selection of appropriate strains and the controlled production of the consortia at scale. Here, we report on an ecology- and biotechnology-based approach to microbial consortium construction that overcomes these issues. We selected nine strains that form a consortium to emulate the central metabolic pathways of carbohydrate fermentation in the healthy human gut microbiota. Continuous co-culturing of the bacteria produces a stable and reproducible consortium whose growth and metabolic activity are distinct from an equivalent mix of individually cultured strains. Further, we showed that our function-based consortium is as effective as FMT in counteracting dysbiosis in a dextran sodium sulfate mouse model of acute colitis, while an equivalent mix of strains failed to match FMT. Finally, we showed robustness and general applicability of our approach by designing and producing additional stable consortia of controlled composition. We propose that combining a bottom-up functional design with continuous co-cultivation is a powerful strategy to produce robust functionally designed synthetic consortia for therapeutic use.

4 November 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
RLRicardo Leon-Sampedro
Ricardo Leon-Sampedro
MBMathilde Boumasmoud
Mathilde Boumasmoud
MRMarkus Reichlin
Markus Reichlin
KPKatia R. Pfrunder-Cardozo
Katia R. Pfrunder-Cardozo
NNNicholas Noll
Nicholas Noll
AHAlex R. Hall
Alex R. Hall
The spread of antibiotic-resistant bacteria in the gut depends on their ability to establish within complex microbial communities. However, the role of various ecological factors in modulating this process, particularly in the absence of antibiotic selection, remains poorly understood. We hypothesize that different strains within the same species vary in their ability to colonize due to distinct interactions with resident microbiota. Using human gut-microbiome samples in replicated anaerobic microcosms with and without antibiotics, we test multiple clinically relevant and phylogenetically distinct Escherichia coli strains carrying extended-spectrum beta-lactamase (ESBL) or carbapenemase plasmids. While antibiotics influence the growth of incoming resistant strains, some are successful even without antibiotics. Growth outcomes depend on a combination of intrinsic growth capacities in relevant abiotic conditions, competition with resident E. coli , and strain-specific shifts in resident community composition. We also detect horizontal transfer of resistance plasmids in some conditions, but transconjugants remain rare across treatments. Here, we show that the success of antibiotic-resistant bacteria depends on strain-specific ecological interactions, helping to explain the spread and persistence of resistance in human microbiomes.

5 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
LALaura Anthamatten
Laura Anthamatten
PBPhilipp Rogalla von Bieberstein
Philipp Rogalla von Bieberstein
CTClémentine Thabuis
Clémentine Thabuis
CMCarmen Menzi
Carmen Menzi
MRMarkus Reichlin
Markus Reichlin
GLGabriel Leventhal
Gabriel Leventhal
Microbiomes are an essential contributor to the metabolic activity in the human gastrointestinal tract. The fermentation of otherwise indigestible nutritional components like dietary fibers relies on a complex interplay of metabolic pathways that are distributed across the individual bacteria. Yet, which of the bacteria are responsible for which parts of the distributed metabolism and how they should be grouped together is insufficiently understood. Here, we present the NicheMap™, an approach to map the different bacterial taxa that make up the gut microbiome onto the different functional niches of microbial carbohydrate fermentation. Our approach uses in vitro measurements of bacterial growth and metabolic activity to identify which bacterial taxa are responsible for which metabolic function in the relevant complex context of whole human fecal microbiomes. We identified ‘characteristic taxa’ selected for by a panel growth substrates representative of dietary components that are resistant to digestion by host enzymes. These characteristic taxa offer predictions of which bacteria are stimulated by the various components of human diet. We validated these predictions using microbiome data from a human nutritional supplementation study. We suggest a template of how bacterial taxonomic diversity is organized along the trophic cascade of intestinal carbohydrate fermentation. We anticipate that our results and our approach will provide a key contribution towards building a structure-function map for gut microbiomes. Having such a map on hand is an important step in moving the microbiome from a descriptive science to an interventional one.

15 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
RLRicardo Leon-Sampedro
Ricardo Leon-Sampedro
MBMathilde Boumasmoud
Mathilde Boumasmoud
MRMarkus Reichlin
Markus Reichlin
KPKatia R. Pfrunder-Cardozo
Katia R. Pfrunder-Cardozo
NNNicholas Noll
Nicholas Noll
AHAlex R. Hall
Alex R. Hall
Understanding the spread of antibiotic-resistant bacteria in human-associated microbial communities, particularly in the gut microbiome, is critical for combating the global resistance crisis. However, the role of various ecological factors, such as intraspecies or interspecies interactions, in modulating this process is poorly understood. We hypothesized that different strains within the same species would exhibit distinct interactions with the resident microbiota, leading to variable invasion outcomes. To test this, we examined the population growth of multiple clinically relevant antibiotic-resistant E. coli strains carrying ESBL and carbapenemase resistance plasmids. We introduced these strains into human gut microbiome samples from healthy individuals, using replicated anaerobic microcosms treated or untreated with antibiotics. We found that while antibiotic exposure significantly influenced the growth of these incoming strains, some were successful even in the absence of antibiotics. The variation in ecological success across strain-microbiome sample combinations was positively associated with the intrinsic growth capacities of the strains in local abiotic conditions and their competitive interactions with resident E. coli . Furthermore, the incoming resistant strains had strain- specific effects on the taxonomic composition of the resident microbiota; different strains not only varied in their growth performance in human microbiomes, in some cases they pushed taxonomic composition of the resident community in different directions. In contrast with phenotypes measured in gut microcosms, metabolic profiles measured across various single-carbon-source environments were not reliable predictors of population growth in human microbiomes. Overall, this controlled design reveals the multi-layered ecological dynamics and strain-specific mechanisms that govern the spread of antibiotic-resistant bacteria in individual human-associated microbiomes.